Vera Therapeutics (VERA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting commenced at 8:00 A.M. Pacific Time on May 21st, 2026, via a virtual platform, with board members, executive team, and auditors present.
The agenda included three proposals: election of directors, ratification of auditors, and an advisory vote on executive compensation.
Voting procedures and rules of conduct were explained, with polls open for all matters.
Board and executive committee updates
Three nominees for Class II directors were presented: Michael Morrissey, Patrick Enright, and James Myers, to serve until the 2029 annual meeting.
Shareholder proposals
Three proposals were submitted: election of directors, ratification of KPMG LLP as auditors for 2026, and an advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vera Therapeutics
- Atacicept advanced toward FDA approval as net loss widened to $121M, with strong cash reserves.VERA
Q1 20268 May 2026 - Atacicept nears FDA approval with strong data, broad label, and robust commercial launch plans.VERA
TD Cowen 46th Annual Health Care Conference1 May 2026 - Director elections, auditor ratification, and executive pay are key 2026 meeting agenda items.VERA
Proxy filing9 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval at the 2026 meeting.VERA
Proxy filing9 Apr 2026 - FDA priority review and strong cash reserves set the stage for atacicept's 2026 launch.VERA
Q4 202526 Feb 2026 - Atacicept demonstrated robust efficacy and safety in IgAN, targeting a multi-billion dollar market.VERA
Corporate presentation30 Jan 2026 - Atacicept shows robust efficacy in IgA nephropathy, with commercialization targeted for 2026.VERA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Atacicept nears pivotal data and broad expansion, targeting multiple autoimmune diseases.VERA
R&D Day 202419 Jan 2026 - Atacicept achieved durable biomarker reductions and near-normal kidney function over 96 weeks.VERA
Study Result18 Jan 2026